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ABSTRACT 
Title of the study: Current tuberculosis epidemic in the North-western federal region of 
Russia: drug resistance, molecular epidemiology and risk factor analysis 
Researcher: Anton Baranov 
Supervisors: Gunnar A Bjune, MD, PhD, professor (University of Oslo, Norway); Andrey O. 
Mariandyshev, MD, PhD, professor (Northern State Medical University, Russia); Ulf R. Dahle, PhD, 
senior scientist (Norwegian Institute of Public Health, Norway) 
Settings: The study was carried out in 4 administrative territories of the North-western federal 
region of Russia Federation. Namely, in Arkhangelsk oblast, Murmansk oblast, Republic of Karelia, 
and Republic of Komi.  
Study design: An epidemiological cross-sectional study. 176 M. tuberculosis strains were 
isolated from tuberculosis patients diagnosed with new cases of pulmonary tuberculosis in the North-
western federal region of Russia during 2004, 2005 and 2006. The isolates were tested for drug 
susceptibility with BACTEC 460 and typed with Restriction Fragment Length Polymorphism (RFLP) 
method and spoligotyping. 
Objectives: Superior objectives: 
1. To describe the level of drug resistance and the genetic diversity of Mycobacterium 
tuberculosis (M. tuberculosis) in the North-western federal region of Russia in new spear-
positive civilian patients. 
2. To disclose risk factors which are associated with drug resistant strains of M. tuberculosis 
circulating in the North-western federal region of Russia. 
Specific objectives: 
1. To describe the drug resistance patterns of M. tuberculosis isolates to the first-line and 
some of the second-line drugs in new smear-positive cases in the North-western federal region 
of Russia to outline the magnitude of the problem in these communities. 
2. To describe the genetic diversity of the M. tuberculosis population isolated from patients 
residing in the study area by use of  RFLP and spoligotyping. 
3. To reveal social, demographical and medical characteristics of the study population that are 
significantly associated with possession of drug resistant tuberculosis among the current 
collection of M. tuberculosis strains from the North-western federal region of Russia. 
Results: Rates of drug resistance for the first-line anti-tuberculosis drugs in M. tuberculosis 
isolates were quite high – drug resistance to isoniazid and rifampicin, the most effective anti-
tuberculosis drugs, was detected in 44.9% and 31.3% of cases, respectively. Drug resistance for the 
second-line anti-tuberculosis drugs was lower, with the highest rates of resistance found to 
 8
ethionamid– 32.9% of cases, capreomycin – in 17.0% of all isolates and kanamycin – 14.2%. 
By use of spoligotyping we could reveal that there are three main lineages of M. tuberculosis 
which are prevalent in the study area. The Beijing lineage was identified in 46.8% of isolates. 25.1% 
of all the strains belonged to the T lineage, and 12.2% - to the Haarlem lineage. 
By assimilating spoligotyping with RFLP data, we found 5 clades of M. tuberculosis isolates, 
with the biggest clade (about half of all cases) characterized by similar RFLP patterns. This clade 
mainly contained isolates belonging to the Beijing lineage. 
On the other hand, the Beijing lineage, despite the fact of having similar RFLP pattern in most 
isolates, had one subgroup with heterogeneous RFLP patterns. 
The Beijing lineage was found to be significantly associated with multi-drug resistance (MDR), 
drug resistance to all first-line anti-tuberculosis drugs and drug resistance to ethionamid, in comparison 
with the other two prevalent lineages of M. tuberculosis – T and Haarlem. 
Conclusions: M. tuberculosis strains circulating in the North-western federal region of Russia 
possess high rates of drug resistance to the first-line anti-tuberculosis drugs, which have increased in 
comparison with the collection of strains isolated in Arkhangelsk oblast 6 years ago (1). The core of 
the current M. tuberculosis population was constituted by the Beijing lineage, to which about half of 
M. tuberculosis strains were assigned.  
The Beijing family had significantly higher percentage of MDR, drug resistance to all first-line 
drugs, and drug resistance to ethionamid, than the other two most prevalent families – T and Haarlem. 
This could be one of the factors favoring the abundance of this particular lineage. 
Many RFLP clusters comprised of isolates from different lineages were shared by strains from 
different territories in the North-western federal region of Russia. This suggested that in order to 
handle the tuberculosis epidemic in the North-western federal region of Russia, one may need to 
strengthen anti-tuberculosis programs in all regions. 
Reporting of the results: The results of the current study were reported to the population 
studied, to the local health and community leaders, to funding agencies that supported the study.  Some 
data from the current research was presented in a poster at the 17th European Congress of Clinical 
Microbiology and Infectious Diseases/25th International Congress of Chemotherapy (31 March-3 
April 2007, Munich, Germany) and published as an on-line supplement to the following journals - 
Clinical Microbiology and Infection, Volume 13, supplement no.1 and International Journal of 
Antimicrobial Agents, March 2007, Volume 29, supplement 2. One article has been published in a 
peer-reviewed Russian journal indexed in MedLine (2). Several papers based on the results of the 
current study will be submitted to peer-reviewed international journals. 
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LIST OF ABBREVIATIONS 
 
AFB – acid-fast bacilli 
ARTD – Arkhangelsk Regional Anti-tuberculosis Dispensary 
bp – base pairs 
CDC - United States Centers for Disease Control and Prevention 
CRISP - clustered regularly interspaced short palindromic repeats 
DNA – deoxyribonucleic acid 
DR – direct repeats 
DST – drug susceptibility testing 
DVR - direct variant repeat 
EQA - external quality assurance 
HIV – human immunodeficiency virus 
IS6110 – insertion sequence 6110 
IUATLD – International Union Against Tuberculosis and Lund Diseases 
M. tuberculosis – Mycobacterium tuberculosis 
MDR – multi-drug resistance 
MDR-TB – multi-drug resistant tuberculosis 
MIRU – mycobacterial interspersed repetitive units 
NIPH – Norwegian Institute of Public Health 
OR – odds ratio 
PCR – polymerase chain reaction 
RFLP – restriction fragment length polymorphism 
RNA – ribonucleic acid 
SPIDR region - spacer interspersed direct repeats region 
WHO – World Health Organization 
XDR – extensive drug resistance 
XDR-TB – extensively drug-resistant tuberculosis 
ZN method – Ziehl-Neelsen method 
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INTRODUCTION 
Tuberculosis has claimed its victims throughout much of known human history. This is an 
ancient disease that spread in epidemic form among susceptible people. It has had a large economic 
impact on societies, along with a huge influence on human creativity; on the lives of individuals in 
music, art and literature (3). One of the biggest recent impacts is noted in the advances in biomedical 
science and healthcare.   
Some estimates suggest that the genus Mycobacterium originated 150 millions years ago (4). 
On the basis of molecular genetic analysis of M. tuberculosis, Gutierrez at al. concluded that early 
progenitor of M. tuberculosis was present in the East Africa as early as 3 million years ago and may 
have infected early hominids at that time (5).  However, it is likely that modern strains of M. 
tuberculosis, originate from a common ancestor that underwent an evolutionary bottleneck 15,000-
20,000 years ago (4). 
During the last few decades, a chain of scientific evidences has improved our understanding of 
this infection. One of the most dramatic events happened on March 24, 1882, when Hermann Heinrich 
Robert Koch made his famous presentation Die Aetiologie der Tuberculose, to the Berlin Physiological 
Society (4). In that presentation he demonstrated the identity on the causative agent of tuberculosis – 
the tubercle bacillus. In 1905 Koch was awarded Nobel Prize in Medicine or Physiology for this 
elucidation of the etiology of tuberculosis. 
Another major event in tuberculosis history which should be particularly noted is the discovery 
of chemotherapy. Before introduction of modern chemotherapy, about 50% of tuberculosis patients 
died within 5 years (6). The first discovered therapeutic agent with efficacy in the treatment of 
tuberculosis was para-amino salicylic acid (PAS) by Jorgen Lehmann in 1943. In 1943 Gerhard 
Domagh discovered thiosemicarbazone and in 1944 Albert Schatz , Elisabet Bugie, and Selman 
Waksman reported the discovery of streptomycin, the first antibiotic effective against M. tuberculosis 
(4). For this discovery Selman Abraham Waksman was awarded the Nobel prize in Medicine or 
Physiology in 1952. Isoniazid, the first oral mycobactericidal drug and rifampicin followed in 1952 
and 1957, respectively, starting a new era of tuberculosis treatment. 
In the beginning of the 20th century , while knowledge of tuberculosis advanced with the work 
of Villemin, Koch, von Pirquet, and others, the disease rates began to decline (4). The explanation for 
this decline remains elusive. Improved social and living conditions, herd immunity resulting from 
natural selection of a genetically more resistant population, improved nutritional status and 
understanding of infectious epidemics, as well as pasteurization, sanatorial isolation of infectious cases 
etc. are all considered important contributors to this rapid decline. However, none of these measures 
are fully adequate to explain the decline in tuberculosis rates. Falling case rates were accompanied by 
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an apparent shift of disease occurrence in older individuals. 
In Europe and North America this decline has continued up to the present time with temporal 
resurgence of the disease in some countries during the periods of World War I and World War II (4). 
In contrast, nowadays tuberculosis remains a leading cause of death from a single infectious agent in 
low-income countries. 
Despite advances in tuberculosis research, available anti-tuberculosis drugs, well established 
control programs in many countries, and international attention to this disease, it is estimated that more 
than 50 million people will die from tuberculosis between 1998 and 2020. Under the current 
tuberculosis control conditions, this number may even approach 70 million (6).  
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LITERATURE REVIEW 
Current world tuberculosis epidemiology 
Tuberculosis is the leading cause of death from a curable infectious disease (7). Overall, one-
third of the world’s population is currently infected with the tuberculosis bacillus (8). 5-10% of people 
who are infected with tuberculosis bacilli (but who are not infected with Human Immunodeficiency 
virus (HIV)) become sick or infectious at some time during their life. People with HIV and 
tuberculosis infection are much more likely to develop tuberculosis.  
In 2004 tuberculosis incidence was estimated to be 8.9 million cases per year and mortality 
from tuberculosis – 1.7 million people (8). Approximately 80% of the estimated number of all new 
tuberculosis cases worldwide are arising in 22 high-burden countries (9). They are (in alphabetical 
order): Afghanistan, Bangladesh, Brazil, Cambodia, China, Congo, Ethiopia, India, Indonesia, Kenya, 
Mozambique, Myanmar, Nigeria, Pakistan, Philippines, Russian Federation, South Africa, Tanzania, 
Thailand, Uganda, Viet Nam, Zimbabwe. 
In 2004, the per capita tuberculosis incidence was stable or falling in five out of six WHO 
regions, but growing at 0,6% per year globally. The exception is the African region, where the 
tuberculosis incidence was still rising, following the spread of HIV (9). In Eastern Europe (mostly, 
countries of the former Soviet Union), the incidence per capita increased during the 1990s, peaked 
around 2001, and has since fallen (9). 
The high tuberculosis incidences in many countries are believed to represent the tip of the 
problem regarding eradication of tuberculosis worldwide. Drug resistant forms of tuberculosis are 
becoming more and more common.  International medical experts are worried about the spread of M. 
tuberculosis strains harboring drug resistance to several drugs. One of the most dangerous forms of 
resistance is multi-drug resistance (MDR) which is defined as a resistance to at least isoniazid and 
rifampicin, the two most effective anti-tuberculosis drugs (10). Patients having drug resistant forms of 
tuberculosis require specific combinations of second- and third-line anti-tuberculosis drugs. These 
drugs are often less effective than the first-line drugs; they produce more side-effects and require 
longer medication periods. As a result, the cure rates among patients harboring multi-drug resistant 
isolates range from 6% to 59% (10).  
Moreover, in March 2006, the World Health Organization (WHO) and the United States 
Centers for Disease Control and Prevention (CDC) reported extensively drug-resistant tuberculosis 
(XDR-TB) as a serious, emerging threat to public health and tuberculosis control (11). XDR-TB is 
defined as resistance to at least rifampicin and isoniazid (which is the definition of MDR), in addition 
to any fluoroquinolone, and to at least one of the three injectable drugs used in anti-tuberculosis 
treatment: capreomycin, kanamycin and amikacin (11). Treatment of XDR-TB is even more 
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complicated than MDR, because the choice of available drugs effective in such forms of tuberculosis is 
very limited. 
In the 1990s World Health Organization and International Union Against Tuberculosis and 
Lung Diseases initiated a project “Anti-tuberculosis drug resistance in the world” aiming at mapping 
drug resistance patterns of M. tuberculosis to the first-line drugs in different countries of the world. 
The latest, third report was released in 2004 and it includes data from 77 settings or countries collected 
between 1999 and 2002, representing 20% of the global total new smear-positive tuberculosis cases 
(10). According to WHO/IUATLD data, prevalence of resistance in new cases to at least one anti-
tuberculosis drug ranged from 0% (Andorra, Malta, Iceland)  to 57,1% in Kazakhstan (median 10,2%). 
The highest prevalence of MDR in new cases of tuberculosis were noted in Kazakhstan (14,2%), Israel 
(14,2%) Tomsk oblast – Russian Federation (13,7%), Karakalpakstan – Uzbekistan (13,2%), Estonia 
(12,2%), Liaoning province – China (10,4%), Lithuania (9,4%), Latvia (9,3%), Henan province – 
China (7,8%), Ecuador (6,6%). Of note is the fact that there were just two oblasts (out of 89) from 
Russia that were included in the last report.  
Drug resistance in previously treated cases was higher (10). The median prevalence of 
resistance to at least one drug was 18,4%, with the highest prevalence, 82,1% in Kazakhstan. The 
highest prevalence of MDR in previously treated cases was reported in Oman (58,3%) and Kazakhstan 
(56,4%). Among countries of the former Soviet Union the median prevalence of resistance to the four 
drugs was 30%, compared with a median of 1,3% in all other settings. 
In that report by WHO/IUATLD, it has also been noted about a significant increase in 
prevalence of any resistance and MDR in a number of settings in comparison with data from previous 
reports, both in new and previously treated cases.  
Description of the tuberculosis epidemiology is incomplete without mentioning such reservoirs 
of tuberculosis infection as correctional facilities. In a study on the epidemiology of tuberculosis in 
European prisons, A. Aerts and colleagues (12) analyzed data from 22 countries. The median 
tuberculosis notification rate (the total number of tuberculosis patients in prisons over the cumulative 
number of prisoners) was 232 per 100 000 inmates (0–17 808). In the countries surveyed, tuberculosis 
incidence rates in prisons were 8–35 times higher than in the total population. Consequently, despite 
the fact that the majority (90.9%) of the participating countries reported performing active screening 
for tuberculosis on entry into prison, with a median detection rate of 393/100 000 (42–2362), the 
burden of tuberculosis in prisons is quite high.  
After being released, prisoners, among whom there could be undetected tuberculosis cases or 
patients who have not yet completed treatment for tuberculosis, also represent an infectious risk 
outside the correctional facility. Additionally, correctional facilities are not isolated societies as 
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inmates have contact with non-incarcerated people such as guardians, visitors and medical staff. 
Prisons thus represent a considerable infectious reservoir which sustains tuberculosis epidemics 
worldwide. 
 
Tuberculosis in Russia 
Overall data on tuberculosis morbidity and mortality in Russia was covered by the state during 
the years when Soviet Union was isolated from the rest of the world. It is only in the early 1990s, after 
dismantlement of Soviet Union, when these data became available to the public.  
 It is known that during much of the 20th century tuberculosis morbidity and mortality rates in 
Russia were declining (13). As a result, morbidity rates fell to 34,2 cases per 100 000 population in 
Russia in 1990 (13). 
But, after dismantlement of Soviet Union in 1991 followed by military conflicts in Chechnya 
and economic crisis in 1998, tuberculosis morbidity and mortality raised again. The reasons for that 
could have been disruption and breakdown of management systems in administrative and medical 
areas, general economic destruction, military conflicts, negative changes in the environment, intensive 
migration, increasing unemployment and homelessness, and loss of financial support for tuberculosis 
programs (13). In 1999, tuberculosis morbidity and mortality rates constituted 85,2 and 20 cases per 
100 000 population, respectively (13). Similar trends were observed in the other countries of the 
former Soviet Union (14).  
At the present, due to the flaws in registration and reporting systems of tuberculosis in some 
parts of Russia, poor access to diagnostic facilities and, in some settings, lack of standardization of 
diagnostic laboratory routine techniques, overall data on tuberculosis incidence and mortality is 
unavailable. But on the basis of the available data, some estimates have been proposed. 
According to WHO estimates, in 2004 the tuberculosis incidence in Russia was 115 (all 
cases/100 000 population/year), prevalence 160 (all cases/100 000 population) and mortality 21 
(deaths/100 000 population/year) (9). The prevalence of HIV infection in adult tuberculosis patients 
(15-49 years) was quite low and constituted 6.8% (9). 
Available and reliable data on drug resistance of circulating M. tuberculosis strains in different 
parts of Russia is even more fragmented. There are just several areas where adequate and standardized 
laboratory drug susceptibility testing (DST) techniques for epidemiological analysis have been applied 
so far. Currently, data on drug resistance in patients from civil sector is available for Ivanovo oblast, 
Tomsk oblast, Samara oblast, Orel oblast, St. Petersburg, Arkhangelsk oblast;  and for some prison 
settings, namely, Arkhangelsk prison, Samara prison, Mariinsk prison, Kemerovo prison (14). Thise 
data is presented in Table 1. In all these settings the proportions of drug resistance and MDR in 
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previously treated cases were higher than in new cases of tuberculosis. In the areas where there are 
data available for comparison of drug resistance levels between the civil sector and the prison sector 
(such as in Arkhangelsk and Samara), higher rates of drug resistance of M. tuberculosis were found in 
the prison sectors. 
16 
Table 1. Tuberculosis drug resistance in different parts of Russia (modified table is taken with authors 
kind permission from publication: Toungoussova OS, Bjune G, Caugant DA. Epidemic of tuberculosis 
in the former Soviet Union: social and biological reasons. Tuberculosis (Edinb ) 2006 Jan;86(1):1-10) 
Region Year Drug resistance 
  New cases Treated cases 
Ivanovo oblast 2000 MDR1 9% MDR 26% 
  Isoniazid 22% Isoniazid 33% 
  Rifampin 16% Rifampin 43% 
  Ethambutol 10% Ethambutol 30% 
  Streptomycin 18% Streptomycin 46% 
Tomsk oblast 2000 MDR 7% MDR 27% 
  Isoniazid 19% Isoniazid 43% 
  Rifampin 8% Rifampin 31% 
  Ethambutol 7% Ethambutol 21% 
  Streptomycin 25% Streptomycin 53% 
Samara oblast 2001 MDR 45%  
  Isoniazid 52%  
  Rifampin 58%  
Orel oblast 1999–2000 Isoniazid 17% Isoniazid 38% 
  Rifampin 4% Rifampin 25% 
  Ethambutol 3% Ethambutol 25% 
  Streptomycin 33% Streptomycin 50% 
St. Petersburg 1990 MDR 18%  
 1999 MDR 36% MDR 22% 
Archangel oblast 1998–1999 MDR 14% MDR 60% 
  Isoniazid 37% Isoniazid 73% 
  Rifampin 14% Rifampin 60% 
  Ethambutol 23% Ethambutol 60% 
  Streptomycin 40% Streptomycin 67% 
Archangel prison 2001 MDR 34% MDR 55% 
  Isoniazid 43% Isoniazid 65% 
  Rifampin 34% Rifampin 55% 
  Ethambutol 31% Ethambutol 35% 
  Streptomycin 70% Streptomycin 65% 
Mariinsk prison 1999 MDR 26%  
Samara prison 2001 Isoniazid 60%  
  Rifampin 80%  
Kemerovo prison 1999 MDR 23%  
  Isoniazid 66%  
1MDR, multidrug resistance. 
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 The need for standardization and improvement of the quality of routine DST methods currently 
being used at Russian laboratories is recognized. This is important point in order to be able to get high-
quality DST results which are essential for the selection of appropriate anti-tuberculosis drugs and for 
the description of the tuberculosis epidemiology. In 2003, an official Order by the Ministry of Health 
giving thorough instructions on performance of routine DST method which is currently being widely 
used at Russian laboratories – absolute concentration method -  was released (15).  
Another step was undertaken in 2005, when the Federal System for External Quality Assurance 
(EQA) of laboratory assays in Russia was launched in order to raise the quality of routine laboratory 
assays. One of the components of this system is DST of M. tuberculosis isolates.  Under this EQA 
system the panel of 20 WHO M. tuberculosis strains with well-characterized DST pattern is distributed 
annually to every peripheral laboratory performing DST of M. tuberculosis. The results from 
peripheral laboratories are then compared with the actual DST patterns of those strains and decision 
about accreditation of every particular laboratory is drawn.  
 
The tuberculosis epidemic in the North-west Russia 
Tuberculosis remains a burning problem of the healthcare system in the North-western part of 
Russia. In 2004 according to the official statistics, tuberculosis morbidity in the North-western federal 
region of Russia comprised 65,0 per 100 000 and mortality from tuberculosis – 14,0 per 100 000 (16).  
In Arkhangelsk oblast, data from annual report of ARTD from 2004 witnesses that morbidity and 
mortality from tuberculosis constituted 57,9 and 16,8 per 100 000 in the civil sector. But if prison 
sector is included, then these figures rise up to 72,3 for morbidity and 18,5 for mortality per 100 000. 
Epidemiological studies in the North-western part of Russia on drug resistance and molecular 
epidemiology of M .tuberculosis are scarce and future studies should be welcomed. In the civil and 
prison sectors in Arkhangelsk region, however, information is available (17;18). The authors of that 
studies revealed that 25,2% of all strains isolated among patients living outside correctional 
institutions, had MDR and the proportion of the Beijing strains was 44,5% (17). In the prison sector 
the proportion of MDR in new cases was 34,5%, 76,3% of both new and previously treated cases of 
tuberculosis were caused by Beijing strains (18). 
 Data from Arkhangelsk suggests that this region suffers a high incidence of tuberculosis, 
accompanied by high rates of drug resistance. This poses challenges for the local anti-tuberculosis 
program and demand special approaches in order to control the tuberculosis epidemic. This may also 
be the case for other administrative areas within the North-western federal region of Russia. There 
appears to be a great need to gather epidemiological data in the adjacent regions, in order to get an 
overview of the current situation related to the spread of drug resistant tuberculosis and different 
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genotypes of M. tuberculosis. Such data may serve as a supplement for decision-makers and medical 
officials when planning interventions into the current tuberculosis epidemic. 
 
Microbiological testing methods of M. tuberculosis: 
1. Microscopy 
 Simple microscopy of clinical specimens stained by the Ziehl-Neelsen (ZN) method is one of 
the most frequently used laboratory technique for detection of M. tuberculosis. In low-income 
countries, ZN staining followed by simple microscopy is widely used because of its low cost, and high 
specificity and sensitivity. Both specificity and sensitivity are dependant on the procedural standards 
(19). This method confirms diagnosis of tuberculosis by revealing specific AFB and helps to follow-up 
the treatment process of each patient. This technique is quite simple and inexpensive. The results of the 
test are available within 24 hours of sputum collection. 
 There are some other microscopy methods, which differ in the staining procedures. Kinyoun’s 
cold staining is a modification of the classical ZN method that excludes the heating step during 
staining and therefore uses a higher concentration of carbol fuchsin. The quality of the results obtained 
through this method were found to be inferior to ZN method (19). 
Other methods are auramine and auramine-rhodamine staining followed by flourochrome 
microscopy. Because it is easier to detect a fluorescent rod against a dark background, the 
fluorochrome staining method allows the examiner to scan the slide at a lower magnification and thus 
observe a larger area than with ZN-stained smears. These factors reduce the time for screening and 
lead to greater sensitivity. The proficiency testing study of 167 laboratories in the United States found 
that the sensitivity and specificity of the ZN and fluorochrome methods are comparable if the 
procedural standards are followed (19). The authors concluded that because of the little time required 
for the fluorochrome method, laboratories with large specimen numbers may prefer this technique. In 
other cases, the ZN method may be recommended. 
2. Identification tests 
 Identification tests are performed to make sure that the bacilli belong to the species within the 
M. tuberculosis complex. Most identification tests are either based on biochemical features of M. 
tuberculosis (for instance, salicylic test, nitrate reduction test, niacin accumulation test) or on genetic 
analysis (for example, AccuProbe testing kit). Different laboratories chose those test that are 
affordable, reliable and reproducible. 
 Traditionally, in Russia, identification of M. tuberculosis is done according to the Order by 
Ministry of Health №109 from 2003 (15). Bacilli are identified by visual inspection of colonies, 
morphology of colonies, speed of growth, temperature for growth, color of the colonies and salicylic 
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test. 
 At the  NIPH identification is performed by visual inspection of the colonies, a 16S rRNA gene 
hybridization technique (AccuProbe; GenProbe Inc., San Diego, Calif.) as well as standard 
microbiological tests (niacin accumulation and nitrate reduction tests). 
3. Drug susceptibility testing methods (including molecular basis for drug resistance) 
The knowledge on individual DST patterns of M. tuberculosis strains isolated from particular 
patients is essential for prescription of a relevant and effective drug regimen. It is known that drug 
resistance in M. tuberculosis emerge as a result of mutations in particular areas of the genome, 
encoding different proteins involved in the metabolism of this microorganism. The pressure by 
irrelevant chemotherapy favors selection of drug resistant strains possessing such mutations and, in 
turn, this induces higher rates of primary drug resistance. 
All DST methods which are currently available for testing of M. tuberculosis isolates could be 
divided into two groups.  
The first group includes in vitro phenotypic methods. Those methods utilize the principle of 
inhibition of growth of M. tuberculosis isolates in the presence of anti-tuberculosis drugs in the 
medium. Many modifications of DST methods based on this approach have been developed. Some of 
them are based on solid media – absolute concentration, proportion methods etc.; the others are based 
on liquid media – BACTEC 460, BACTEC MGIT, BacT/Alert etc. Growth detection on liquid media 
vary: it is resulting release of radioactive carbon dioxide, change of the colorimetric properties of the 
medium or detection of emerging fluorescence. 
In vitro phenotypic methods usually are rather time-consuming because of slow growth of M. 
tuberculosis on media. Nevertheless, most of them are considered to be “gold standards” in DST. 
The second group comprised by molecular biology methods which detect mutations in the 
genome of M. tuberculosis, known to confer drug resistance to some specific drugs. Such methods are 
fast, but require knowledge on the mechanisms of drug resistance to different drugs. At the moment, 
mutations conferring resistance to rifampicin, isoniazid, ethambutol and streptomycin are most well-
characterized 
Among rifampicin-resistant isolates mutations within a 81-bp region which is a part of the rpoB 
gene that encode a beta subunit of the DNA-dependant RNA polymerase is common. Mutations in 
some codons within this core region are more frequently observed among rifampicin resistant isolates. 
Codons 531, 526 and 516 are  associated with high levels of resistance (20). 
For isoniazid the situation is more complex – mutations conferring resistance have been 
reported to occur in four different genetic loci: katG, encoding catalase-peroxidase; inhA involved in 
fatty acid elongation; ahpC encoding alkyl hydroperoxide reductase, and oxyR involved in the 
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regulation of oxidative stress. In addition, it is believed that mutations in other undescribed genes may 
also encode isoniazid resistance. Despite this complexity, mutations within codon 315 of the katG are 
reported frequently and are often associated with resistance to isoniazid. 
Mutations causing resistance to ethambutol have been found in the embCAB which codes for 
different arabinosyl transferases which have a role in lipoarabinomannan and arabinogalactan 
synthesis. 
Resistance against streptomycin is induced by mutations within rrs, which codes for 16SRNA 
and rpsL, which produces the ribosomal protein 12S. 
 
 Traditionally, in Russia DST is carried out by absolute concentration method on solid media. 
This method has several disadvantages. The most important of them is that this method demands quite 
much time before conclusions about susceptibility or resistance of testing strains can be drawn. 
Usually it takes 10-12 weeks until final results are obtained. 
 BACTEC 460 (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) is a method which is 
based on DST on liquid medium (21). The principle of BACTEC 460 method is radiometric detection 
of the metabolic activity of M. tuberculosis. The resulting release of 14C02 from liquid medium is 
measured automatically using an ionization chamber. The amount of growth, indicated by changes in 
the growth index (ΔGI) in the medium with known drug concentration as compared to that in the 
control bottle, is correlated to a presence or absence of resistance in 1% of inoculum. If an isolate 
grows beyond a specific growth index compared with the control, it is considered resistant to that 
specific antimicrobial agent (21). 
 BACTEC 460 is regarded as fast and handy method for routine use (21-23). But it also has 
several limitations which are well known and include manual loading, potential risk of cross 
contamination related to invasive reading, lack of computerized data management and accumulation of 
radioactive waste (21). Despite of these disadvantages, BACTEC 460 has much more advantages. For 
instance, the results of DST with this method could be available within one week. This method does 
not have such disadvantages, which are present when performing DST on solid media, as inactivation 
of antimicrobial agents during preparation of agar and destruction of the drugs during long incubation 
(24). Moreover, higher reproducibility of this method, i.e. absence of significant discrepancies between 
laboratories when performing DST for the same strains of M. tuberculosis, have been demonstrated 
(23). And the most important point is that all first-line drugs (21;25) and some of the second line drugs 
(21;23) have internationally standardized recommendations for usage in this method. That is why, 
currently, this method is treated as “gold standard” in DST.  
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4. Molecular typing methods 
By use of DNA-DNA hybridization studies it has been demonstrated that the members of the 
M. tuberculosis complex are extremely conserved and 99,9% of their DNA is homologus (26). The 
first molecular tools to characterize circulating strains of M. tuberculosis in order to investigate 
outbreaks of tuberculosis were implemented in laboratories during the 1990s (27). Since that time a lot 
of different genetic techniques, using different genomic regions as a probe, has been elaborated for in-
depth investigation of strains of M. tuberculosis (28;29). These markers, with different levels of strain 
discrimination, include various short repetitive sequences and insertion sequences (IS), of which 
IS6110 is the most commonly used for strain typing (26).  Tandem repeats such as the polymorphic 
GC-rich sequence, the major polymorphic tandem repeat, the triplet GTG, various exact tandem 
repeats, direct repeats (DR) and mycobacterial interspersed repetitive units (MIRU) have also been 
used for several applications of strain typing. The DNA polymorphism associated with these genetic 
markers can be visualized by a variety of methods, such as restriction fragment length polymorphism 
(RFLP) typing, polymerase chain reaction (PCR), DNA hybridization, sequencing, or a combination of 
these methods (26). 
The choice between DNA typing methods strongly depends on several considerations: they 
should preferably be reproducible, rapid, inexpensive, easy to perform and directly applicable to 
clinical material. The degree of discrimination of the method and stability of the marker should be 
appropriate for the research question to be addressed.  
The most commonly used techniques are RFLP typing and PCR-based method – spoligotyping, 
investigating the direct repeat (DR) genomic region of M. tuberculosis (29). These techniques allow 
one to distinguish between isolates of M. tuberculosis. In different parts of the world, including Russia, 
Beijing family of M. tuberculosis has been found to be prevalent and also to be significantly associated 
with drug resistance (17).  
Currently, according to the last international recommendations, the Beijing genotype defined as 
hybridizing to at least three of the nine spacers 35 to 43 and with an absence of hybridization to 
spacers 1 to 34 by spoligotyping, or carrying 80% or more similarity to 19 reference RFLP patterns 
(30). This genotype of M. tuberculosis was found to be abundant in a previous study from 
Arkhangelsk, Russia  (17;18).  
 
Risk factors for drug resistance of M. tuberculosis 
Increasing drug resistance in many pathogenic bacteria is a common event in developing 
countries nowadays (31). The burden of infectious diseases in developing countries is high and 
availability of resources for modern diagnostics, treatment and patient management is limited. Low-
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quality antibacterials and non-compliance to the standard drug prescription regimens are contributing 
to the problem. For instance, the increase of drug resistance is observed in enteric pathogens (e.g, 
Salmonella enterica serotype Typhi, Salmonella enterica serotype Paratyphi, Shigella flexneri, 
Shigella dysenteriae type I, Vibrio cholerae), respiratory pathogens (Streptococcus pneumoniae, 
Mycobacterium tuberculosis), sexually transmitted infections (Neisseria gonorrhea), nosocomial 
infections (Staphylococcus aureus, gram-negative bacteria) (31). These facts give us special concerns 
in performing DST methods. 
M. tuberculosis is a slowly-growing microorganism. Due to this fact, much time is needed 
between diagnostics of tuberculosis in an individual patient (which in most settings is diagnosed by 
finding of typical acid-fast rods in sputum samples) and drawing conclusion about drug resistance 
pattern of a particular M. tuberculosis isolate. It can take up to 2 month before the final DST results 
become available for an individual patient. But in order to get a picture of a “typical patient having 
drug resistant form of tuberculosis”, which will make health workers to become especially focused on 
diagnostics and treatment of such person even before getting DST results, risk factor analysis has been 
applied in many settings of the world.  
Many studies have been done for revealing factors associated with drug resistance of M. 
tuberculosis. But the primary concern is risk factors for MDR tuberculosis, because, as it has been 
mentioned before, this form of tuberculosis is especially costly to handle in terms of resources and 
dangerous from epidemiological point of view. 
In a recent systematic review paper, Faustini A. and colleagues analyzed published literature on 
risk factors for MDR tuberculosis in Europe (32). Twelve European countries were represented in the 
review: the former USSR, Poland, Hungary and Turkey from eastern Europe; Italy, UK, France, 
Switzerland, Spain, Portugal, Netherlands and Germany from western Europe.  
The pooled risk was 10.23 times higher in previously treated than in new cases of tuberculosis, 
but wide heterogeneity has been noted between studies. Study design and geographical area were 
associated with increased MDR tuberculosis risk estimates in previously treated patients: the risk 
estimates were higher in cohort studies carried out in western Europe (RR 12.63; 95% CI 8.20 to 
19.45) than in eastern Europe (RR 8.53; 95% CI 6.57 to 11.06).  
The review found that MDR tuberculosis patients were more likely to be foreign born (OR 
2.46; 95% CI 1.86 to 3.24), although the strength of the association was much less for previous 
treatment. There was a clear association observed between MDR tuberculosis and age under 65 years 
(OR 2.53; 95% CI 1.74 to4.83), but association was weak and more heterogeneous for ages under 45.  
Association between male gender and MDR was found significant (OR 1.38; 95% CI 1.16 to 
1.65), but MDR-TB patients were more likely to be male in western Europe, where previous treatment 
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was the most important determinant of MDR-TB. In eastern Europe, where the risk of transmission is 
greater, male sex was not a risk factor for MDR-TB. 
The pooled risk of MDR-TB and positive HIV status was statistically significant (OR 3.52; 
95% CI 2.48 to 5.01). Faustini A. and colleagues warned that this could have been affected by a 
selection bias occurring in favour of HIV infected individuals among cases studied for sensitivity. This 
hypothesis is supported by the high proportions of HIV patients (32–52%) among those studied for 
drug sensitivity, which is unlikely to reflect the actual prevalence of HIV among tuberculosis cases. 
In Russia, several studies have been done on revealing risk factors associated with MDR 
tuberculosis. In Ivanovo oblast, homelessness was the only risk factor for drug resistance in new cases 
of MDR tuberculosis (33). In Tomsk oblast, factors associated with MDR in new cases of tuberculosis 
were good residence (it was defined as owning your own home, or residing in a cooperative apartment 
or community apartment) (OR 2.6, 95%CI 1.1–6.0) and treatment default (OR 5.3, 95%CI 2.4–11.6) 
(34). Female gender, history of previous treatment for tuberculosis and interruption of present 
treatment were found significant in a dataset consisting of new and previously treated patients in 
Arkhangelsk oblast (35). In Samara region, overall multivariate analysis in tuberculosis patients from 
civil and prison sectors showed that being male, having a history of tuberculosis, previous or current 
treatment for more than 4 weeks and advanced disease with cavitation are highly significant risk 
factors for single drug resistance and MDR-TB (36). History of incarceration was found to be 
significant only in Samara oblast. 
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OBJECTIVES OF THE STUDY 
 
Our study delineates the magnitude of the problem of drug resistance, in particular MDR, and 
characterize molecular epidemiology of M. tuberculosis strains circulating in the North-western federal 
region of Russia. This study is covering a wider area than previous studies performed in Arkhangelsk.   
Superior objectives: 
1. To describe the level of drug resistance and the molecular epidemiology of M. tuberculosis in 
the North-western federal region of Russia among new spear-positive patients. 
2. To disclose risk factors which are associated with drug resistant strains of M. tuberculosis 
circulating in the North-western federal region of Russia. 
 
Specific objectives: 
1. To determine drug resistance of M. tuberculosis to the first-line and some second-line drugs in 
new smear-positive cases in the North-western federal region of Russia, in order to outline the 
magnitude of the problem in this community. 
2. Describe the molecular epidemiology of M. tuberculosis isolated from patients from the study 
area with IS6110 RFLP and spoligotyping. 
3. To describe social, demographical and medical characteristics of the study population that may 
be associated with drug resistant tuberculosis in the North-western federal region of Russia. 
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MATERIALS AND METHODS 
Study area 
The study was carried out in 4 administrative territories of the North-western federal region of 
Russian Federation. Namely, in Arkhangelsk oblast, Murmansk oblast, Republic of Karelia, Republic 
of Komi.  
According to the last census of enumeration from 2002, the population of the study areas 
comprised 1 336 539 people in Arkhangelsk oblast, 892 534 in Murmansk oblast, 716 281 in Republic 
of Karelia and 1 018 674 in Republic of Komi. Total population at risk is 3 964 028 people or 28,4% 
of all people registered in the North-western federal region of Russia. 
 
Patients and sample size 
A sample of tuberculosis patients who were registered as new cases of tuberculosis at one out 
of four regional anti-tuberculosis dispensaries serving civil population in Arkhangelsk oblast, 
Murmansk oblast, Republic of Karelia or Republic of Komi (Russia) was collected. 
Because of the long-run practical performance of laboratory testing of the strains of M. 
tuberculosis, time-consuming shipment of the material for testing and requirements for the sample size 
for this study, we have established following inclusion criteria: 
1. Patients from civil sector consecutively diagnosed as new cases of pulmonary tuberculosis 
during one month in 2004, 2005 and 2006. 
2. Isolation of all M. tuberculosis strains has been performed before initiation of the treatment 
with anti-tuberculosis drugs. 
Exclusion criteria: 
Tuberculosis patients previously treated with anti-tuberculosis drugs. 
Representativeness of the sample: 
All consecutively diagnosed new cases of pulmonary tuberculosis isolated during one month in 
2004, 2005 and 2006 were included in the current study. 
 
 
Mycobacterial strains 
 In total, 192 M. tuberculosis strains were sent to the National Reference Laboratory for 
Mycobacteria at NIPH from the Russian laboratories. A total of 16 strains were contaminated or could 
not be re-cultivated in Oslo. These cultures and corresponding patients were excluded from the current 
study.  
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The final number of the strains processed at the NIPH was 176. This number constituted 13 
strains from Republic of Komi, 33 strains from Arkhangelsk oblast, 17 strains from Murmansk oblast 
and 18 strains from Republic of Karelia - all isolated during 2004. During 2005 the NIPH received 25 
strains from Arkhangelsk oblast and in 2006, 21 strains from the Republic of Karelia, 19 strains from 
Murmansk oblast and 30 strains from Arkhangelsk oblast completed the current collection. 
 
Drug susceptibility testing method 
 BACTEC 460 
 BACTEC 460 is regarded as “gold standard” in performing DST - that is why we used this 
method to characterize drug resistance patterns of M. tuberculosis strains in our sample. 
 In brief, procedures for this method involve cultivation of M. tuberculosis strains on medium, 
dissolvement in 0,9% NaCl solution, adjustment to appropriate optical density with photometer, 
inoculation of bottles containing drugs of known concentrations and daily readings of the results until 
the criteria for termination of the process are archived. 
First-line anti-tuberculosis drugs have well-standardized concentrations for use in this method 
(21;25) which well correspond to in vivo concentration of these drugs. Following drug concentrations 
were used in our study: isoniazid 0.2 mg/ml, rifampicin 2.0 mg/ml, ethambutol 5 mg/ml, streptomycin 
6 mg/ml, pyrazinamid 100 mg/ml.  
 Concentrations of the second-line drugs are much poorer standardized because of lack of large-
scale multicenter studies(21;23;37;38). In our study we used following drug concentrations: amikacin 
1.0 mg/ml, ofloxacin 2.0 mg/ml, kanamycin 5 mg/ml. The situation with ethionamid and capreomycin 
is more complex, because before March 2006, the corresponding in vitro concentrations for 
ethionamid were considered to be 1.25 mg/ml and 5 mg/ml (because of different standards). But in 
March 2006 two publications based on big experimental databases were published by German and 
British authors, which proposed another concentration – 2.5 mg/ml (37;38). For capreomycin the 
situation is simpler – before the beginning of 2006, the recommended corresponding in vitro 
concentrations were1.25 mg/ml and 10 mg/ml. But when the before-mentioned papers were issued, 
just one concentration remained out of two – 1.25 mg/ml. That is why all M. tuberculosis strains 
received in 2004 and 2005 (n=106) were tested with two different concentrations of capreomycin (1.25 
mg/ml; 10 mg/ml) and ethionamid (1.25 mg/ml; 5 mg/ml), and strains received in 2006 (n=70) were 
tested with just single concentrations of capreomycin (1.25 mg/ml) and ethionamid (2.5 mg/ml). DST 
with amikacin was carried out just on the strains received in 2006 (n=70), because it is just in 2006 
when WHO highlighted the significance of this drug for diagnosis of XDR tuberculosis. 
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Molecular typing methods 
RFLP typing 
IS6110 RFLP typing has been internationally standardized with regard to the choice of 
restriction enzyme, probe and size markers. This has allowed interlaboratory comparisons by entering 
DNA fingerprints into a computer and processing with special programs (29). This fact, along with the  
high discriminatory power of the method, explains why it is widely used in different parts of the world. 
Several international databases of RFLP patterns from a wide geographical area have been established. 
RFLP typing is widely used for studying epidemiology and outbreaks of tuberculosis and for 
revealing possible laboratory-contamination (false positive samples) because of the high stability of 
IS6110. The half-life of IS6110 RFLP is estimated to be 3-4 years (39). 
This method is based on differences in the number of IS6110 copies, ranging from 0 to about 
25, and their chromosomal positions. 
In brief, the procedures for this method are following (29): DNA was extracted from bacterial 
cultures, purified and digested with restriction enzyme PvuII. Restriction fragments were separated on 
an agarose gel and transferred to a DNA binding membrane. DNA was hybridized to the 254-bp 
internal PCR fragment of IS6110 and visualized by use of a digoxigenin-dUTP labeling and detection 
kit (Boehringer).  
Spoligotyping 
Spoligotyping represent a rapid method which allow the identification and typing of M. 
tuberculosis complex bacteria even directly in clinical samples. But the level of differentiation by 
spoligotyping is inferior to that of RFLP typing for strains carrying five or more copies  of IS6110, but 
higher for strains with less than five copies. 
This method is based on polymorphisms present at one particular chromosomal locus, which is 
called the “direct repeat” region (DR). This region is present in M. tuberculosis complex bacteria and 
was first described by Hermans et al, who sequenced this region in Mycobacterium bovis BCG (40). 
This locus has been designated the spacer interspersed DR (SPIDR) region and was recently renamed 
by Jansen et al as the “clustered regularly interspaced short palindromic repeats” (CRISPR) region 
(41). This locus contain multiple, well-conserved 36 base pairs (bp) DRs interspersed with 
nonrepetitive 34- to 41-bp DNA spacer sequences. One DR and its neighbouring non-repetitive spacer 
is called “direct variant repeat” (DVR).  The vast majority of M. tuberculosis strains contain one or 
more IS6110 elements in the DR region (40).  
With spoligotyping, the presence or absence in the CRISPR region of 43 spacers of known 
sequence can be detected by hybridization of PCR-amplified DNA to a set of immobilized 
oligonucleotides, representing each of the unique spacer DNA sequences (40). Differences between 
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spoligotype patterns have been shown to be due to deletions of spacer sequences in the CRISPR region 
(40), by transposition of IS6110 elements (42;43) and, probably, by homologous recombination 
between adjacent or distant DRs (44). 
The first step in the method is to amplify the DR region of a given strain by PCR. The primers 
used are based on the sequence of the DR, and allow the amplification of the spacer(s) between the DR 
targets (Figure 1).  
 
 
Figure 1. Principle of the in vitro amplification of DNA within the DR region of 
M.tuberculosis complex bacteria (taken from Spoligotyping kit manual) 
 
 
The PCR products differ in length because of two reasons: First, the product contains several 
DVRs; second, the product itself can act as a primer, and become elongated with one or more DVRs. 
A biotin labeled primer is used, so that all the reverse strands synthesized are biotin labeled. Then 
amplified DNA is hybridized to a set of spacer oligonucleotides, covalenly linked to a membrane and 
this membrane is incubated in streptavidin peroxidase, which binds to biotin label on the PCR 
products. After that, hybridization signals are visualized by enhanced chemiluminescence detection 
system on X-ray films (40). 
The results of the spoligotyping are shown as presence or absence of spots corresponding to 
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spacers present in the isolate. For the purporse of convenience, these results are transformed into 
standardized octal code (45). 
Spoligotyping is a good method for rapid molecular characterization of M. tuberculosis 
isolates. It helps assign strains into different lineages, and appears well suited for evolutionary studies 
on the phylogeny of M. tuberculosis. This method helps us to get a general picture of the molecular 
profiles of circulating strains. For individual information related to contact tracing, spoligotyping 
represents a rough classification tool as it examines a small genomic area of the whole genome. 
Spacers can only be lost, thus diversity is unidirectional and conclusions of molecular characterization 
may be difficult to make. However, the significance of this method for molecular characterization and 
assignment into phylogenetic lineages appear unequalled by other typing methods for M. tuberculosis 
strains. 
On the basis of compilation of available data on worldwide spoligotype patterns, the fourth 
international spoligotype database was published recently (46). It contain data on 39 295 strains from 
122 countries, which are tentatively classified into 62 clades/lineages. This is a useful and powerful 
tool for the identification of M. tuberculosis isolates. 
Repeated attempts failed to produce reliable spoligopatterns for 5 of the 176 isolates. The 
troubleshooting to complete these patterns were not considered within the scope of the current thesis. 
These strains are to be analyzed at a later time.  
 
Data collection 
A special structured questionnaire was designed in order to retrospectively collect information 
from medical records on patient’s medical, social or demographic characteristics (see Appendix). We 
were able to collect information regarding the patients, whose isolates were sent to the NIPH in 2006. 
This information was analyzed and associations with microbiological characteristics of the 
individually isolated strains were determined by statistical analysis. Experience from the Arkhangelsk 
study was taken into account when designing the questionnaire for the current study. 
 
Data analysis 
SPSS for Windows, version 14.0, and module ‘Statcalc - Statistical calculator’ from EpiInfo 
version 6.04d (CDC, USA and WHO, Geneva, Switzerland) were used for statistical analysis. 
Associations between proportions were expressed as Odds Ratios. Degrees of association between 
proportions were assessed using χ2 with Yate’s correction and confidence intervals. If expected values 
in cells were less then 5, Fisher’s exact test was used. Logistic linear regression was applied in search 
for demographic, social and medical factors which are significantly associated with drug resistance in 
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M. tuberculosis. 
The software “Bionumerics” (AppliedMaths, Kortrijk , Belgium) version 1.5 was applied for 
the analysis of RFLP patterns of M. tuberculosis strains. Before the analysis, RFLP data were 
normalized according to genetic markers with standardized molecular weight. To analyze the RFLP 
patterns the Dice similarity coefficient was used with the following position tolerance settings – 
optimization 1.0%, position tolerance 1.0%, change towards end of fingerprint 0%, minimum height 
0%, and minimum surface 0%. Cluster analysis was performed using the unweighted pair-group 
average method. A cluster was defined as two or more M. tuberculosis strains exhibiting 100 percent 
similarity of RFLP patterns under specified position tolerance settings.  
 
Ethics of the study 
The study was conducted according to the Helsinki declaration. All collected information was 
kept in a safe place without possibility that a third party could access it. In the reports of the results it is 
impossible to identify identity of any particular tuberculosis patient. 
Ethical clearance of the study was evaluated and approved by the Department of International 
Community Health, University of Oslo, Norway.  
 
Definitions 
In our study we used the following official definitions by IUATLD and WHO (47): 
A case of tuberculosis: a patient in whom tuberculosis has been bacteriologically confirmed, or 
has been diagnosed by a clinician. 
Pulmonary tuberculosis (sputum smear-positive):  
a) two or more initial sputum examinations positive for acid-fast bacilli (AFB), or 
b) one sputum smear examination positive for AFB plus radiographic abnormalities consistent 
with active pulmonary tuberculosis as determined by clinician, or 
c) one sputum smear positive for AFB plus sputum culture positive for M. tuberculosis 
New case of tuberculosis: a patient who have never had treatment for tuberculosis or who has 
taken anti-tuberculosis drugs for less than one month. 
Treatment outcomes for smear-positive pulmonary tuberculosis patients:  
a) cure: a patient who is sputum smear negative in the last month of treatment and on at least 
one previous occasion 
b) treatment completed: a patient who has completed treatment but who does not meet the 
criteria to be classified as a cure or a failure 
c) treatment failure: a patient who is sputum smear positive at five month or later during 
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treatment 
d) died: a patient who dies for any reason during the course of treatment 
e) defaulter: a patient whose treatment was interrupted for two consecutive month or more 
f) transfer out: a patient who has been transferred to another recording and reporting unit and 
for whom the treatment outcome is not known. 
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RESULTS 
 
Drug susceptibility patterns of M. tuberculosis strains 
The results on the prevalence of drug resistance to every single tested first- and second-line 
drug are presented in Table 2. Strains exhibiting intermediate and resistant results were classified as 
drug resistant, because we considered intermediate results to be a manifestation of low-level drug 
resistance.  Among the first-line drugs intermediate results were very rare – there were just one strain 
which produced intermediate result to streptomycin and two strains with intermediate drug resistance 
pattern to pyrazinamid. Intermediate results for the second-line drugs were obtained for capreomycin 
at concentration of 1.25 mg/ml – 12 strains, ethionamid at concentration 5 mg/ml – 2 strains and 
ethionamid at concentration 1.25 mg/ml – 1 strain. 
Drug resistant results were obtained in 44.9% of all M. tuberculosis isolates when performing 
DST for isoniazid, 44.3% - for streptomycin, 31.3% - for rifampicin, 30.1% - for ethambutol and 
29.0% - for pyrazinamid. 
Drug resistance to the second-line drugs was low for amikacin, ofloxacin and capreomycin (at 
concentration 10 mg/ml) - 4.3%, 3.4% and 1.9% of all isolates, respectively. For capreomycin at 
concentration 1.25 mg/ml and kanamycin drug resistance was registered in 17.0% and 14.2% of all 
cases, respectively. The highest rate of drug resistance among second-line drugs was found for 
ethionamid at concentration 1.25 mg/ml – in 77.4%, then comes ethionamid at concentration 5 mg/ml 
– 33.0% and ethionamid at concentration 1.25 mg/ml – 32.9% of all cases. 
MDR was revealed in 30.7% of all M. tuberculosis isolates. 
We have found one strain from Arkhangelsk oblast which exhibited XDR pattern, i.e. it was 
resistant to isoniazid, rifampicin, ofloxacin, kanamycin and capreomycin. In addition it was resistant to 
the rest of first-line drugs and to ethionamid at concentration 1.25 mg/ml. The only two drugs that it 
was susceptible to were ethionamid at concentration 5 mg/ml and capreomycin at concentration 10 
mg/ml. 
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Table 2. Results of drug susceptibility testing of M. tuberculosis strains isolated from patients 
in the North-western federal region of Russia with BACTEC 460 
 Number of tested isolates Number of drug resistant 
strains, abs.1(%) 
1st line drugs:   
Isoniazid 176 79 (44.9%) 
Rifampicin 176 55 (31.3%) 
Ethambutol 176 53 (30.1%) 
Streptomycin 176 78 (44.3%) 
Pyrazinamid 176 51 (29.0%) 
2nd line drugs2:   
Kanamycin 176 25 (14.2%) 
Ofloxacin 176 6 (3.4%) 
Ethionamid (1.25 mg/ml) 106 82 (77.4%) 
Ethionamid (2.5 mg/ml) 70 23 (32.9%) 
Ethionamid (5 mg/ml) 106 35 (33.0%) 
Capreomycin (1.25 mg/ml) 176 30 (17.0%) 
Capreomycin (10 mg/ml) 106 2 (1.9%) 
Amikacin 70 3 (4.3%) 
Selected combinations of drugs   
MDR (isoniazid + rifampicin) 176 54 (30.7%) 
XDR (MDR+ofloxacin+one of the 
following drugs: amikacin, 
kanamycin or capreomycin) 
1763 1 (0.6%) 
1 abs. – absolute number of isolates with drug resistance 
2 ethionamid and capreomycin were used in several concentrations because the relevant in vivo doses are unknown 
3 In the first two recieved batches of strains, sent in 2004 and 2005 (n=106), drug susceptibility testing for amikacin was 
not performed. It was performed only for the last batch of strains (n=70), because it is just in 2006 when WHO highlighted 
the significance of this drug for diagnosis of XDR tuberculosis. As a consequence, rate of XDR strains in our set may be 
underestimated 
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Spoligotyping of M. tuberculosis strains 
To the date of submission of the current thesis we had 171 M. tuberculosis strains out of 176 
typed by spoligotyping.  Spoligotype patterns and lineage assignment based on the SpolDB4 (46) are 
presented in Table 3. 
Based on the spoligotype data, one could conclude that there are three main lineages prevalent 
in the study area. The Beijing lineage accounted for 46.8% of all isolates, while 25.1% belonged to the 
T family, and 12.2% were assigned to the Haarlem family. The remaining 15.9% were shared by 
LAM, MANU, U, CAS and S lineages. Only 3 strains remained undesignated to any known family. 
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Table 3. Spoligotype patterns of M. tuberculosis strains isolated from patients in the North-
western federal region of Russia (n=171) 
Number of strains Pooled prevalence
(n = 171) of lineages, abs.(%)
ffffffffffffffffffffffffffffffffffggggggggg Beijing 76
ffffffffffffffffffffffffffffffffffffggggggg Beijing-like 1
ffffffffffffffffffffffffffffffffffggffggggg Beijing-like 1 80 (46.8%)
ffffffffffffffffffffffffffffffffffggggggfff Beijing-like 2
ffffffffffffffffffffffffggggggggffffgggggff T1 1
fffffffffffffffffffgggggggggfffgffffggggggg T1 1
gggfggggggggggggggggggggggggggggffffggggggg T1 1
ggggggffffffffffffggggggggggggggffffggggggg T1 1
gggggggfgggggffffffffffffgggggggffffggggggg T1 1
gggggggggfgggfggggggggggggggggggffggggggggg T1 1
ggggggggggfffffffffffffffgggggggffffggggggg T1 1
ggggggggggfgfffffffffffffgggggggffffggggggg T1 1
ggggggggggggffffffffffffffggggggffffggggggg T1 3 43 (25.1%)
gggggggggggggffffffffffffgggggggffffgggfggg T1 2
gggggggggggggffffffffffffgggggggffffggggggg T1 3
ggggggggggggggfffgffffffffffffffffffggggggg T1 1
ggggggggggggggggggggggggggggggggffffggfgggg T1 1
ggggggggggggggggggggggggggggggggffffggggggg T1 10
ggggggffffffffffffggggggggggggggffffgggffff T1_RUS2 1
ggggggggggggggggggggggggggggggggffffgggfggg T2 6
ggggggggggggggggggfgggffggggggggfffffffffgg T4 1
ggggggggggggggggggfgggggggggggggffffggggggg T4 1
ggggggggggggggffffffffffggggggggffffggggggg T5_RUS1 5
ggggggggggggggfffgffffffggggggggffffggggggg T5_RUS1 1
gfggggggggggggggggggggggggggggfgffffggggggg Haarlem3 2
ggggggggggggggggggggggggggggggfgffffggggggg Haarlem3 6
gggggggffggggggggffffffffffgfffgffffggggggg Haarlem4 1
gggggggffgggggggggfgffffggggfffgffffggggggg Haarlem4 1
gggggggffgggggggggggffffggggfffgffffgggffgg Haarlem4 1
gggggggffggggggggggggggggfggfffgffffggggggg Haarlem4 1 21 (12.2%)
gggggggffgggggggggggggggggggfffgffffgggfggg Haarlem4 2
gggggggffgggggggggggggggggggfffgffffggggggg Haarlem4 2
gggggggggggffgggggggggggggggfffgffffggggggg Haarlem4 1
ggggggggggggfgggggggggggggggffffffffggggggg Haarlem4 2
ggggggggggggfgggggggggggggggfffgffffggggggg Haarlem4 2
ggfgggggggggggggggggffffggggggggffffggggggg LAM1 1
ggggggggggggggggggfgggfffgggggggffffggggggg LAM10 1
ggggggggggggggfgggggffffggggggggffggggggggg LAM9 1 9 (5.3%)
ggggggggggggggggggggffffggggggggffffffggggg LAM9 1
ggggggggggggggggggggffffggggggggffffggggggg LAM9 5
gggggggggggggffffffffffffgggggggffggggggggg MANU2 3
ggggggggggggggffffffffffffffffffffggggggggg MANU2 1
ggggggggggggggfffgffffffffffffffffggggggggg MANU2 1 9 (5.3%)
ggggggggggggggggggggffffggggggggffggggggggg MANU2 1
ggggggggggggggggggggggggggggggggffggggggggg MANU2 3
gggggggggffffffffffffffffffffffffffffgggggg U 2
ggggggggggggggggggggggggggggffffffffggggggg U 1 4 (2.3%)
ggggggggggggggggggggggggggggggffffffggggggg U 1
gggffffgggggggggggffffffffffffffffggggggggg CAS 1 1 (0.6%)
ggfgggggffgggggggggggfggggggggggffffggggggg S 1 1 (0.6%)
gfffffffffggggggggggggggggggggggffffgggfggg Undesignated strain
2 1 1 (0.6%)
ggffgggffgggggggggggggggggggfffgffffggggggg Undesignated strain 1 1 (0.6%)
gggggggggggffgggggggggggggggfffgffggggggggg Undesignated strain 1 1 (0.6%)
Spoligotype pattern Lineage1
1 Assignment of M. tuberculosis strains into different lineages described in SpolDB4 
2 Undesignated strain : Not decribed in SpolDB4
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Restriction Fragment Length Polymorphism typing results 
The RFLP data of all the strains from the current population are presented in Figure 2.  
By use of visual inspection of the RFLP patterns and the dendrogram one may suggest that  
several clades of M. tuberculosis are circulating in the study area. 
The first clade has a high rate of clustering, which evidence of  recent transmission. Most of the 
isolates assigned to this clade belong to the Beijing lineage. This clade constitute the core of the 
current tuberculosis epidemic because of high proportion of such isolates (about half of all isolates) 
and high levels of similarity which suggest recent transmission.  
The other 4 clades could be distinguished by combining the spoligotyping data with the RFLP 
data. These strains do not have the high rates of clustering, as the first clade revealed. However, they 
are grouped together on the basis of high genetic similarity. The low clustering rates suggest lower 
transmission rates, but all isolates are closely related to at least one other isolate. This epidemiological 
characteristic suggests that these strains have been circulating in the area for a long time, and that they 
represent historic, or indigenous strains. The shallow dendrogram may also suggest that those strains 
could exhibit longer latency periods, lower virulence or presence of conditions favoring the 
transmission of first clade strains. 
The second clade is formed mainly by the T family. This is the second largest lineage 
circulating in the community. We found one cluster containing two isolates in this clade and, 
generally, we can observe that the level of similarity between strains in this clade was higher then in 
clades 3, 4 and 5. 
M. tuberculosis isolates assigned to clades 3, 4 and 5 exhibited highly similar RFLP patterns to 
other isolates sharing the same clade, but were classified as strains belonging to different families. 
Most of them belong to T and Haarlem lineages. 
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Figure 2. Dendrogram demonstrating RFLP patterns of M. tuberculosis isolates from the 
North-western federal region of Russia (n=176) 
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It is well-known that the Beijing strains have a big deletion within the CRISP region, which 
prevents hybridization with the first 34 spacer oligonucleotides during spoligotyping. This lead to a 
lower discriminatory power of spoligotyping of the Beijing strains because of the low number of 
possible variations in spoligotype patterns. 
In order to increase the discriminatory power of spoligotyping in Beijing strains, we plotted a 
separate similarity tree of RFLP patterns of Beijing strains (Figure 3). There we can distinguish 3 
subgroups within the current Beijing isolates. 
The first subgroup contains 18 isolates (22.5% of all Beijing isolates) and the second subgroup 
contains 44 isolates (55.0% of all Beijing isolates). These subgroups have high rates of clustering and 
high similarity between each other. These isolates represent recently transmitted strains in the 
community. 
Third subgroup with 18 isolates (22.5%), on the contrary, is quite heterogeneous in regard to 
the number and location of IS6110 sequences. Those strains are not that successfully transmitted, as 
previous two subgroups. We can speculate that they have lost favoring factor, or they just are varying 
in some other ways from the first two subgroups. 
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Figure 3. Dendrogramm built up by RFLP patterns of M. tuberculosis strains belonging to 
Beijing genotype (n=80) 
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Risk factor analysis 
Social, demographic and medical characteristics of the study population are presented in Table 
4. Data on patients’ education and marital status are not presented because in about half of all analyzed 
medical records this information was absent.  
The mean age of tuberculosis patients was 40.1 years (standard deviation 14.2). Two thirds of 
all tuberculosis patients were males, most of them were smoking and about half of them were alcohol 
abusers. Known contact with tuberculosis patients within one year before the onset of the disease was 
reported just by 20 (40%) patients. Most of the patients were living in flats and half of them were 
jobless. 8 (16%) patients were previously imprisoned. Chronic obstructive pulmonary disease was 
found in 5 (10.0%)  and diabetes - in 1 (2.0%) patient. 
The results of the simple microscopy of the first portion of sputum were reported as negative in 
16 (32.0%) of cases (but, still, the bacilli were found later in one or two next sputum portions). 2 
(4.0%) sputum samples were classified as 1-9 bacilli in 100 viewing fields. 14 (28.0%) patients 
produced sputum samples with grade “+”. 10 (20.0%) and 8 (16.0%) sputum sample were classified as 
“++” and “+++”, respectively. 
We applied logistic regression model in order to find statistically significant explanatory 
variables among demographic, social and medical characteristics of the patients in regard to MDR-TB 
and resistance to all first-line anti-tuberculosis drugs. In the analysis we found no statistically 
significant variables (logistic regression models are not presented in this manuscript). The most 
feasible explanation for this could be small sample size or actual absence of such explanatory 
variables. 
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Table 4. Selected social, demographic and medical characteristics of the tuberculosis patients 
from the North-western federal region of Russia (n=50) 
Variable Variable value Number of patients Percentage 
gender males 33 66.0% 
 females 17 34.0% 
smoking no 17 34.0% 
 yes 31 62.0% 
 unknown 2 4.0% 
alcohol abuse no 26 52.0% 
 yes 21 42.0% 
 unknown 3 6.0% 
known contact with tuberculosis no 26 52.0% 
patient within the last one year yes 20 40.0% 
 unknown 4 8.0% 
housing homeless 2 4.0% 
 hostel 1 2.0% 
 flat 42 84.0% 
 Own house 5 10.0% 
occupation jobless 26 52.0% 
 permanent job 17 34.0% 
 retired 6 12.0% 
 unknown 1 2.0% 
previous imprisonment no 40 80.0% 
 yes 8 16.0% 
 unknown 2 4.0% 
chronic obstructive pulmonary no 37 74.0% 
disease yes 5 10.0% 
 unknown 8 16.0% 
diabetes no 48 96.0% 
 yes 1 2.0% 
 unknown 1 2.0% 
 
 43
 
The Beijing genotype was found to be the most prevalent in the study area. Thus, we compared 
the odds ratios of drug resistance for the Beijing genotype versus other lineages in regard to MDR, 
resistance to all first-line drugs and separate resistance for each second-line drug (Table 5). 
The Beijing lineage was found to possess significantly higher rates of MDR, drug resistance to 
first-line drugs and drug resistance to ethionamid, when compared to those levels of other prevalent 
genotypic groups. Resistance to capreomycin, however, was less common among Beijing isolates, than 
for other genotypes of M. tuberculosis. Resistance to this drug was significantly associated with 
possession of M. tuberculosis isolates belonging to the Haarlem genotype. 
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Table 5. Drug resistance to the first- and second-line anti-tuberculosis drugs in Beijing 
genotype isolates versus other genotypic lineages of M. tuberculosis 
 Lineages under comparison 
 First 
lineage 
Abs.1 (%) Second 
lineage 
Abs. (%) 
Odds ratio 95% 
Confidence 
interval 
p-value 
MDR2 T 3 (7.0%) 13.33 3.54-59.01 <0.001 
 Haarlem 2 (9.5%) 9.50 1.93-63.34 0.002 
 
 
Beijing 
 
40 (50.0%) 
others 8 (29.6%) 2.38 0.86-6.74 0.11 
Drug resistance to all 
first-line drugs 
T 3 (7.0%) 4.75 1.22-21.49 0.019 
 Haarlem 1 (4.8%) 7.12 0.91-150.96 0.038 
 
 
 
Beijing 
 
 
21 (26.3%) 
others 6 (22.2% 1.25 0.40-4.0 0.87 
Drug resistance to 
ethionamid (2.5) 
T 2 (11.1%) 13.09 2.17-101.93 0.002 
 Haarlem 1 (6.7%) 22.91 2.45-534.54 0.001 
 
 
 
Beijing 
 
 
18 (62.1%) 
others 2 (25.0%) 4.91 0.69-43.36 0.11 
Drug resistance to 
capreomycin 
T 5 (11.6%) 1.09 0.31-3.97 0.88 
 Haarlem 8 (38.1%) 0.23 0.07-0.80 0.01 
 
 
 
Beijing 
 
 
10 (12.5%) 
others 7 (25.9%) 0.41 0.12-1.38 0.13 
Drug resistance to 
kanamycin 
T 3 (7.0%) 3.87 0.98-17.73 0.54 
 Haarlem 0 (0%) undefined undefined 0.02 
 
 
 
Beijing 
 
 
18 (22.5%) 
others 4 (14.8%) 1.67 0.46-6.55 0.56 
Drug resistance to 
ofloxacin 
T 0 (0%) undefined undefined 0.16 
 Haarlem 0 (0%) undefined undefined 0.58 
 
 
 
Beijing 
 
 
5 (6.3%) 
others 1 (3.7%) 1.73 0.18-41.06 1.0 
Drug resistance to 
amikacin 
T 0 (0%) undefined undefined 0.28 
 Haarlem 0 (0%) undefined undefined 0.54 
 
 
 
Beijing 
 
 
3 (10.3%) 
others 0 (0%) undefined undefined 1.0 
1 Abs. – absolute number of strains 
2 MDR – multi-drug resistance (resistance to at least isoniazid and rifampicin) 
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 DISCUSSION 
This is the first epidemiological study on the prevalence of drug resistance and molecular 
epidemiology of M. tuberculosis circulating in several areas in the North-western federal region of 
Russia. 
Looking into DST results (Table 2), it was concluded that drug resistance to the first-line drugs 
was more prevalent than to the second line drugs. This was not unexpected, because first-line drugs 
have been used for a longer time in the history of treatment of tuberculosis and second-line drugs 
normally are being used much more rarely. 
The fact that drug resistance to the first-line drugs was high, in particular resistance to the most 
effective anti-tuberculosis drugs – isoniazid and rifampicin (44.9% and 31.3% of cases, respectively), 
along with a tendency to increase – when compared to the data from a previous study in the 
Arkhangelsk region (1) - rises serious concerns. In 2001, MDR was diagnosed in 13.5% of new cases 
of pulmonary tuberculosis. Resistance to isoniazid and rifampicin was revealed in 37.1% and 13.5%, 
respsectively of all M. tuberculosis isolates (1). In the present population resistance to pyrazinamid 
was found in 29.0% of cases, this poses serious challenges to the treatment regimes of tuberculosis due 
to the specific pharmacodynamics and pharmacokinetics of pyrazinamid, which make it hard to 
substitute it with any other drug. 
As described in the methodology part, we used capreomycin and ethionamid at different 
concentrations due to the absence of clear recommendations for drug susceptibility testing of these 
drugs with BACTEC 460. For ethionamid we used three concentrations and one of them turned out to 
be too high since 77.4% of all the isolates exhibited resistance at concentration 1.25 mg/ml. The 
remaining concentrations produced similar results (Table 2). Taking this fact into account, along with 
the latest recommendations issued by German and British authors (37;38), we assumed that the most 
relevant concentration for ethionamid is 2.5 mg/ml. In our collection of M. tuberculosis strains, drug 
resistance for ethionamid at this concentration was found in 32.9% of tested isolates. 
The various proportions of drug resistant strains to different concentrations of capreomycin,  
was 15%. In accordance with current recommendations (37;38) we regarded the concentration of 1.25 
mg/ml to represent relevant therapeutic doses.  The large number of strains exhibiting intermediate 
susceptibility to this drug, at this concentration may represent emerging low-level drug resistance to 
capreomycin in the study community. It may also reflect uncertainties related to correct  concentrations 
for capreomycin while performing DST. Standardization of methods for DST to second-line drugs was 
not considered within the scope of the current thesis, thus the latest internationally validated reference 
concentration was used. Drug resistance to capreomycin at concentration 1.25 mg/ml was detected in 
17.0% of cases. 
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RFLP represents the gold standard for molecular characterization of M. tuberculosis strains.  It 
allows investigation into tuberculosis epidemiology, population diversity, contact tracing and 
assessment of degree of similarity between different isolates.  
We assimilated the data from both spoligotyping and RFLP to describe the dynamics of 
transmission and prevalence of different M. tuberculosis lineages in the current study population 
(Figure 2). Interpretation of this data suggested the presence of five main clades of M. tuberculosis, 
circulating in the North-western federal region of Russia. The most prevalent clade, contained the 
Beijing lineage. But this lineage consisted of two similar subgroups as well as a small heterogeneous 
group of M. tuberculosis strains (Figure 3). 
Many clusters were found to be shared by strains isolated from patients from different regions 
in the North-west Russia. It was thus concluded, that despite the distance between patients’ residence, 
they were infected with genetically related strains. This may reflect recent migration processes in 
North-west Russia, which may pose a challenge to control the epidemic of tuberculosis in isolated 
areas without simultaneous strengthening of the tuberculosis control programs in adjacent territories. 
When looking into the rates of drug resistance to the first- and second-line drugs among Beijing 
isolates versus other genotypes of M. tuberculosis we found significantly higher levels of MDR, drug 
resistance to first-line drugs and drug resistance to ethionamid, compared to the T and Haarlem 
lineages. 
High rates of drug resistance to first-line drugs among Beijing isolates may represent one factor 
explaining the high prevalence of this genotype in the study community. Resistant cases may be 
infectious for longer periods and require longer time for diagnosis. The low efficiency of second-line 
drugs and possibly altered metabolism of resistant isolates may also promote transmission and 
resistance to additional drugs. As a consequence, a patient infected with drug-resistant M. tuberculosis 
may remain infectious for a longer period, than a susceptible case. Moreover, in a previous study in 
Arkhangelsk it was found that some strains from the Beijing lineage did not loose their fitness 
(measured as speed of growth) on acquisition of drug resistance (48) . This might thus contribute to the 
success of this particular lineage in the study community. 
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CONCLUSIONS 
1. The core of the current epidemic of tuberculosis in the North-western federal region of 
Russia is constituted by the Beijing lineage, which was harbored in about half of new cases 
of tuberculosis. There are also high levels of the T and Haarlem lineages in the region. 
2. The Beijing family had the highest clustering levels among the circulating families and 
constituted two highly similar subgroups as well as one heterogenous subgroup of strains. 
3. The Beijing family was significantly associated to MDR, drug resistance to the first-line 
drugs and drug resistance to ethionamid when compared to the other prevalent families. 
This may contribute to explain the abundance of this lineage. 
4. Many RFLP clusters included strains from different territories in the North-west federal 
region of Russia.  
5. Comparing of the level of drug resistance with the data from previous study in the 
Arkangelsk region (1), we concluded that there is a trend towards amplification of drug 
resistance among strains circulating in this geographic area. 
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RECOMMENDATIONS 
We found that many RFLP clusters were shared by strains isolated from patients from different 
territories in the North-western federal region of Russia, regardless of the clade to which they 
belonged. This suggested that strengthening of the tuberculosis control programs in all regions are 
needed, and should be synchronized. 
The level of resistance to first-line drugs had increased during the last 6 years (1). Tuberculosis 
cases with high rates of first-line drug resistance are difficult to cure and require longer diagnostic 
periods with available DST methods. This prolongs the infectious period for such patients and 
facilitate resistance to additional drugs. Thus, rapid diagnostics of drug resistance to the first-line 
drugs, in particular isoniazid and rifampicin, is very important to stop the ongoing transmission of 
drug-resistant tuberculosis. 
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APPENDIX 
 
Data collection form 
Date of collection of information (дата сбора информации) <____>______________2006 
Place where patient was registered (медучреждение, где был зарегистрирован больной) 
__________________________________________________________________________ 
I. Patient information (информация о больном) 
1. Culture number in russian laboratory (номер культуры в российской лаборатории) ______ 
2. Gender (пол): ο male (муж), ο female (жен) 
3. Date of birth (дата рождения) ____________________  4. Age (возраст) ___________  
5. Weight (вес) _________kg (кг) 
6. Height (рост)_________cm (см) 
7. Marital status (семейное положение):  
ο married (женат, замужем), ο single (холост), ο divorced (разведен), ο widowed (вдовец) ο 
living together (гражданский брак) 
8. Education (образование):  
ο primary (начальное), ο secondary (среднее), ο college (среднее специальное),  
ο incomplete higher (неполное высшее), ο higher (высшее). 
III. Medical information (медицинская информация) 
9. Smoking (курение): ο no (нет), ο yes (да).  
10. Narcotics abuse (наркотическая зависимость): ο no (нет), ο yes (да). 
11. Alcohol abuse (алкогольная зависимость): ο no(нет), ο yes (да). 
12. Contact with another patient having tuberculosis (контакт с больным легочным туберкулезом в 
течение последнего года): 
 ο no (нет), ο yes (да) 
13. COPD (ХНЗЛ): ο no (нет), ο yes (да): 
 13.1 If yes, then (если да, то): 
ο bronchial asthma (бронх. астма)   ο chronic bronchitis (хр. бронхит) 
ο bronchoectatic disease (бронхоэктат. болезнь) ο lung emphysema (эмфизема)  
ο other COPD diseases (хронический облитерирующий бронхиолит, муковисцидоз, 
биссиноз) 
14. Diabetes (диабет): ο no (нет), ο yes (да).  
15. Immunosuppression (иммуносупрессия): ο no (нет), ο yes (да): 
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 15.1 If yes, then (если да, то): 
ο oncological pathology (онкопатология) 
ο intake of hormones and its reason (гормонотерапия, причина)___________________ 
ο diseases of connective tissues and autoimmune diseases (заболевания соединительной 
ткани и аутоиммунные заболевания) 
ο diseases of blood, specify (заболевания крови, диагноз)_______________________ 
ο other reason (другая причина) ___________________________ 
16. HIV status (ВИЧ): ο negative (отр), ο positive (пол) 
 If positive, then: 
 16.1 Has the patient got antiretroviral therapy (проводилось ли лечение 
антиретровирусными препаратами): ο no (нет) ο yes (да), 
Present TB treatment (настоящее лечение туберкулеза) 
17. Diagnosis (диагноз)__________________________________________________________ 
18. Date of treatment prescription (дата начала лечения) _____________________ 
19. Prescribed anti-TB treatment (назначенные противотуберкулезные препараты) _______ 
____________________________________________________________________________ 
Laboratory data (лабораторные данные): 
20. Smear microscopy (прямая микроскопия):  
If positive, then put the degree (если результат позитивный, то нужно поставить градацию) 
20.1 The first smear (первая порция):     ο neg (отр.)   ο 1-9     ο +     ο ++     ο +++ 
20.2 The second smear (вторая порция): ο neg (отр.)   ο 1-9     ο +     ο ++     ο +++ 
20.3 The third smear (третья порция):     ο neg (отр.)   ο 1-9     ο +     ο ++     ο +++ 
 
21. Chest X-ray before treatment (рентгенологические данные перед началом лечения): 
ο normal (без патологии) 
ο active TB (активный туберкулез) 
ο TB sequellae (остаточные явления после предыдущего случая ТБ) 
ο other pulmonary disease, specify (другое легочное заболевание, указать какое) 
___________________________________________________________________________ 
ο unknown (данные или их описание недоступны) 
21.1 If active TB on X-ray, describe pattern (если выявлен активный туберкулез, опишите 
рентгенологическую форму):  
ο infiltrative (инфильтративный),   ο cavernous (кавернозный) 
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ο fibrous-cavernous (фиброзно-кавернозный), ο miliary (милиарный) 
ο pleuritis (плеврит) 
ο atypical (атипичный)  
 
 
22. Housing (больной проживал):  ο homeless (бездомный), ο hostel (общежитие) 
ο flat (квартира),  ο house (дом) 
23. Occupation (занятость): 
ο pupil (учащийся школы или училища), ο student (студент), ο unemployed (безработный),  
ο employed (работающий): ο physical work (физ. труд),  
ο mental work (умств. труд),  
ο medical staff (мед. работник) 
ο retired (пенсионер) 
24. Being in prison (пребывание в заключении): ο no (нет), ο yes (да) 
If yes, then (если да, то): 
24.1 How many times (сколько раз)_________,  
24.2 Date of the commencement of the last imprisonment and release (месяц и год начала 
последнего заключения и освобождения): _______________, 24.3 _____________ 
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